2024 Annual Symposium - The Society of Toxicologic Pathology (STP)
2024 STP Annual Symposium



Innovative Therapeutics: Biology, Toxicologic Pathology, and Regulatory Perspectives

Scientific Co-Chairs: Dharani K. Ajithdoss, BVSc, MVSc, PhD, DACVP, DACVM, Regeneron Pharmaceuticals; Elizabeth L. Buza, DVM, DACVP, University of Pennsylvania; and Kiran S. Palyada, BVSc, MVSc, PhD, DACVP, DABT, Pfizer Inc.

Continuing Education Chair: Melanie Greeley, DVM, PhD, DACVP, Charles River Laboratories

Continuing Education Co-Chair: Debra A. Tokarz, DVM, PhD, DACVP, EPL, Inc.

View the Preliminary Program

We are excited to bring the 43rd Annual Symposium of the Society of Toxicologic Pathology to Baltimore, Maryland, June 16–19, 2024. The theme of the meeting is “Innovative Therapeutics: Biology, Toxicologic Pathology, and Regulatory Perspectives.” We are fortunate to be living in an era of enormous scientific advancements that are paving the way for the discovery, development, and approval of novel drug molecules including viral vector-based gene therapies, cell-based therapies, RNA-based therapies, and protein degraders. Furthermore, advancements in drug delivery systems are on the rise. These developments will be discussed at the conference, so prepare to be enthralled by what is in store for you.

Dr. James Wilson, University of Pennsylvania, an innovator and pioneer in the field of gene therapy, will kick off the symposium on Monday morning with his Keynote talk on the “AAV-Based Gene Therapies.” This will be seamlessly followed by the first scientific session co-chaired by Drs. Juliette Hordeaux and Larry Whiteley. This session will focus on AAV immunology and AAV-related toxicities in multiple organ systems. Drs. Ingrid Cornax and Brain McIntosh will chair the afternoon session that focuses on the current state of adoptive cell therapies and their preclinical safety findings.

Tuesday morning session will focus on RNA-based therapies chaired by Drs. Adam Michel and Jessica Grieves. In addition to an overview of oligonucleotide drugs, the speakers of this session will share their experience on safety assessment of various RNA-based therapeutic modalities including ASOs and siRNAs. The afternoon session chaired by Drs. Rani Sellers and Shan Naidu will focus on mRNA-based therapies with select examples of applications, clinical pathology, and regulatory considerations.

The focus of Wednesday morning session will be on protein degraders and this session will be chaired by Drs. Monica Rodrigo and Kiran Palyada. Following an overview, the speakers will discuss toxicology, pathology, and regulatory perspectives of proteins degraders. The final session will be chaired by Drs. Dinesh Bangari and Nick Robinson and will focus on LNP and other drug delivery systems. Current status, toxicity, and regulatory considerations of LNP development will be discussed. In addition, there will be captivating student presentations.

Together with the scientific program mentioned above, there will be plenty of other opportunities for interaction and knowledge sharing, including the poster presentations, Continuing Education Courses, and informal conversations at the Welcome Reception, Awards and Recognition Ceremony, and President's Reception. Please join us for the fascinating discussion on these innovative therapeutic modalities and learn from the experts and colleagues over the course of three days. Baltimore is a diverse and exciting city that is constantly enticing adventurers, explorers, artists, and dreamers. What are you waiting for?

This program (20-1190814) has been approved for 18.25 hours of continuing education credits in jurisdictions that recognize RACE approval.


  •  11190 Sunrise Valley Drive,
    Suite 300, Reston, VA 20191